Drug Trial Radar · NCT02495922
A Phase III Trial on the Effect of Elotuzumab in VRD Induction /Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma
Last checked: Nov 20, 2026Latest source record: Sep 10, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
564
Actual
Start
Jun 2015
Primary completion
Jun 24, 2021
Study completion Jun 24, 2021
Sponsor
- Lead sponsor
- University of Heidelberg Medical CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jul 13, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Trial in patients with newly diagnosed myeloma to evaluate the effect of elotuzumab in induction and consolidation therapy with bortezomib/lenalidomide/dexamethasone and in lenalidomide maintenance treatment
Conditions
- Multiple Myeloma
Interventions
elotuzumabDrug
10 mg/kg in the vein( i.v) on day 1,8 and 15 in induction cycle 1 and 2, on day 1 and 11 in induction cycle 3 and 4 (Arm B1 and B2). 10 mg/kg i.v. on day 1,8 and 15 in consolidation cycle 1 and 2 (Arm A2 and B2), 10 mg/kg i.v. on day 1 and15 in maintenance cycle 1-6, 10 mg/kg i.v. on day 1 in maintenance cycle 7-26 (Arm A2 and B2)
LenalidomideDrug
25 mg per os on day 1-14 in induction cycle 1-4, 25 mg p.o. on day 1-14 in consolidation cycle 1 and 2, 10 mg p.o. on day 1-28 in maintenance cycle 1-3, 15 mg p.o. on day 1-28 in maintenance cycle 4-26 (all arms)
BortezomibDrug
all arms: 1,3 mg/m\^2 subcutaneous on day 1, 4, 8 and 11 in 4 induction cycles, 1,3 mg/m\^2 subcutaneous on day 1, 8 and 15 in 2 cycles of consolidation
DexamethasoneDrug
20 mg per os on day 1,2 and 4,5 and 8,9 and 11,12 and 15 in induction cycles 1 and 2. 20 mg per os on day 1,2 and 4,5 and 8,9 and 11,12 in induction cycles 3 and 4 (Arms A1 and A2). 8 mg per os and 12 mg i.v. on day 1, 8 and 15 and 20 mg per os on days 2,4,5, 9, 11 and 12 in induction cycles 1 and 2. 8 mg per os and 12 mg i.v. on day 1, and 11, 20 mg per os on days 2,4,5,8, 9, and 12 in induction cycles 3 and 4 (Arms B1 and B2). 20 mg per os on days 1,2, 8,9, 15 and 16 in both cycles of consolidation (Arms A1 and B1). 8 mg per os and 12 mg i.v. on days 1, 8 and 15 and 20 mg per os on days 2, 9 and 16 in both consolidation cycles (Arms A2 and B2). 12 mg per os on day 1 and 15 in maintenance cycles 1-6, 12 mg per os on day 1 of maintenance cycles 7 and following (Arms A1 and B1). 4 mg per os and 8 mg i.v. on day 1 and 15 in maintenance cycles 1-6, 4 mg per os and 8 mg i.v. on day 1 of maintenance cycles 7 and following (Arms A2 and B2).
Primary outcomes
What the sponsor says the trial is designed to measure.
- the best of four treatment strategies regarding Progression Free Survival (PFS)Time frame: time from randomization to progression or death from any cause whichever comes first, censored after two years of maintenance therapy (i.e. approx. after 36 months after randomisation)
Locations
68 sites in 1 country. Site status is shown where the registry gives one.
Studienzentrum Aschaffenburg
Aschaffenburg, Germany
MVZ Onkologie gGmbH der Klinikum Mittelbaden gGmbH
Baden-Baden, Germany
HELIOS Klinikum, Klinik für Hämatologie, Onkologie und Immunologie
Berlin, Germany
Onkologisches MVZ Berlin Tegel
Berlin, Germany
Charité Campus Benjamin Franklin, III. Med. Abt. (Hämatologie/Onkologie)
Berlin, Germany
Klinikum Bielefeld, Klinik für Hämatologie, Onkologie und Palliativmedizin
Bielefeld, Germany
Studiengesellschaft Onkologie Bielefeld GbR
Bielefeld, Germany
Hämatologisch-onkologische Schwerpunktpraxis
Bochum, Germany
Medizinische Universitätsklinik, Knappschaftskrankenhaus
Bochum, Germany
Universitätsklinikum Bonn, Medizinische Klinik und Poliklinik III, Schwerpunkt Onkologie, Hämatologie und Rheumatologie
Bonn, Germany
ZAHO, Zentrum für ambulante Hämatologie und Onkologie
Bonn, Germany
Schwerpunktpraxis für Onkologie/Hämatologie
Bottrop, Germany
Klinikum Chemnitz GmbH, Innere Medizin III
Chemnitz, Germany
Universitätsklinikum Köln, Klinik I - Innere Medizin
Cologne, Germany
Onkologisches Studienzentrum Darmstadt
Darmstadt, Germany
Klinikum Darmstadt, Med. Klinik V, Hämatologie/Onkologie
Darmstadt, Germany
HELIOS St. Johannes Klinik, Akademisches Krankenhaus der Heinrich-Heine-Universität Düsseldorf
Duisburg, Germany
MVZ Düsseldorf GmbH
Düsseldorf, Germany
Sana Kliniken Düsseldorf GmbH
Düsseldorf, Germany
Universitätsklinikum Düsseldorf, Klinik für Hämatologie,Onkologie und Klin. Immunologie
Düsseldorf, Germany
Universitätsklinik Erlangen
Erlangen, Germany
St.-Antonius-Hospital Klinik f. Hämatologie und Onkologie
Eschweiler, Germany
Universitätsklinikum Essen, Klinik für Hämatologie
Essen, Germany
Ev. Krankenhaus Essen-Werden gGmbH, Zentrum für Innere Medizin, Klinik für Hämatologie, Onkologie und Stammzelltransplantation
Essen, Germany
Centrum für Hämatologie und Onkologie Bethanien
Frankfurt am Main, Germany
Agaplesion Markus Krankenhaus
Frankfurt am Main, Germany
Universitätsklinikum Frankfurt, Goethe-Universität Medizinische Klinik II
Frankfurt am Main, Germany
Praxis und Tagesklinik Friedrichshafen
Friedrichshafen, Germany
Gemeinschaftspraxis Schmitt/Eulenbuch
Gerlingen, Germany
Justus-Liebig-Universität, Medizinische Klinik IV
Giessen, Germany
Kath. Krankenhaus Hagen gGmbH, Abt. Hämatologie/Onkologie
Hagen, Germany
Universitätsklinikum Hamburg-Eppendorf, II - Med. Klinik und Poliklinik
Hamburg, Germany
Asklepios Klinik Hamburg Altona, II. Med. Klinik
Hamburg, Germany
Evangelisches Krankhaus Hamm gGmbH
Hamm, Germany
Onkologische Schwerpunktpraxis
Heidelberg, Germany
University Hospital Heidelberg, Med. Klinik V
Heidelberg, Germany
Onkologische Schwerpunktpraxis
Heilbronn, Germany
SLK Kliniken Heilbronn, Med. Klinik III
Heilbronn, Germany
Universitätsklinikum des Saarlandes, Innere Medizin I
Homburg, Germany
Westpfalz-Klinikum GmbH
Kaiserslautern, Germany
Showing 40 of 68 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.